NCT05067140 - A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer | Biotech Hunter

Enrollment

152

Participants

Timeline

Start Date

September 2, 2021

Primary Completion Date

May 25, 2027

Study Completion Date

May 25, 2027

Conditions

Prostate Cancer Metastatic

Interventions

DRUG

ARV-766 Part A&B

"Part A: Daily oral dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part B: Oral tablet(s) once daily in 28 day cycles."

DRUG

ARV-766 + Abiraterone Part C&D

"Part C: Daily oral combination dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part D: Combination administered once daily in 28 day cycles.~Parts C\&D: Participants will also receive concomitant corticosteroid and ADT therapy of investigator choice/patient preference"

Trial Locations (23)

10065

Clinical Trial Site, New York

14203

Clinical Trial Site, Buffalo

15232

Clinical Trial Site, Pittsburgh

19144

Clinical Trial Site, Philadelphia

20007

Clinical Trial Site, Washington D.C.

21204

Clinical Trial Site, Baltimore

22031

Clinical Trial Site, Fairfax

22908

Clinical Trial Site, Charlottesville

29572

Clinical Trial Site, Myrtle Beach

32746

Clinical Trial Site, Lake Mary

37203

Clinical Trial Site, Nashville

48201

Clinical Trial Site, Detroit

53705

Clinical Trial Site, Madison

60611

Clinical Trial Site, Chicago

70112

Clinical Trial Site, New Orleans

78229

Clinical Trial Site, San Antonio

90404

Clinical Trial Site, Santa Monica

91010

Clinical Trial Site, Duarte

92037

Clinical Trial Site, La Jolla

92868

Clinical Trial Site, Orange

93720

Clinical Trial Site, Fresno

06510

Clinical Trial Site, New Haven

02114

Clinical Trial Site, Boston